Taken together, the five patient-derived xenografts enabled us to obtain a quite complete overview of intestinal-type gastric cancer tumors, reproducing well the heterogeneity and the complexity of human tumors, showing differences in terms of tumor structure, histology, P53/PD-L1 status, and muscle atrophy, which makes them even more useful in preclinical research, for the development of novel drugs and targeted therapies. This evidence concerns the gene TP53 and gastric cancer.